Author:
Li Ruo-Jing,Ma Lian,Drozda Katarzyna,Wang Jie,Punnoose Ann R.,Jeng Linda J. B.,Maynard Janet W.,Zhu Hao,Pacanowski Michael
Publisher
Springer Science and Business Media LLC
Reference13 articles.
1. Taverna S, Cammarata G, Colomba P, Sciarrino S, Zizzo C, Francofonte D, Zora M, Scalia S, Brando C, Curto AL, Marsana EM, Olivieri R, Vitale S, Duro G. Pompe disease: pathogenesis, molecular genetics and diagnosis. Aging (Albany NY). 2020;12:15856–74.
2. Hahn A, Schanzer A. Long-term outcome and unmet needs in infantile-onset Pompe disease. Ann Transl Med. 2019;7:283.
3. Vanherpe P, Fieuws S, D’Hondt A, Bleyenheuft C, Demaerel P, De Bleecker J, Van den Bergh P, Baets J, Remiche G, Verhoeven K, Delstanche S, Toussaint M, Buyse B, Van Damme P, Depuydt CE, Claeys KG. Late-onset Pompe disease (LOPD) in Belgium: clinical characteristics and outcome measures. Orphanet J Rare Dis. 2020;15:83.
4. U.S. Food and Drug Administration (FDA). Integrated review for NEXVIAZYME™ (Avalglucosidase alfa-ngpt). 2021. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/761194Orig1s000IntegratedR.pdf. Accessed 22 Sep 2022.
5. Do HV, Khanna R, Gotschall R. Challenges in treating Pompe disease: an industry perspective. Ann Transl Med. 2019;7:291.
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献